In accordance with Nasdaq Stockholm AB's decision, following application from the liquidator of Scandion Oncology, the shares of Scandion Oncology will be delisted from Nasdaq First North Growth Market. The last day of trading is on July 11, 2025.
For further information, please contact:
Appointed Liquidator
Phone: +45 21227227
E-mail: info@scandiononcology.com
The information was provided by the contact person above for publication on June 25, 2025 at 17.00 CET.
About Scandion
Scandion Oncology (Scandion) is a clinical-stage biotech company using an innovative drug efflux pump inhibition technique with biomodulation capabilities on ABCG2 and UGT1A1 targets to revert drug resistance.
Drug resistance remains a massive problem in cancer treatment and in the development of new medicines. Scandion's lead compound SCO-101 is currently studying metastatic colorectal cancer (mCRC) in its Phase 2 CORIST trial, while the PANTAX Phase 1 program is developing SCO-101 for pancreatic cancer.
Scandion is based in Copenhagen and is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL). Vator Securities is the Company's certified advisor on Nasdaq First North Growth Market.
Aktien»Nachrichten»SCANDION ONCOLOGY AKTIE»Scandion Oncology A/S: Delisting of the shares of Scandion Oncology - last day of trading July 11, 2025
Scandion Oncology A/S: Delisting of the shares of Scandion Oncology - last day of trading July 11, 2025
© 2025 GlobeNewswire (Europe)
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17:00 | Scandion Oncology A/S: Delisting of the shares of Scandion Oncology - last day of trading July 11, 2025 | In accordance with Nasdaq Stockholm AB's decision, following application from the liquidator of Scandion Oncology, the shares of Scandion Oncology will be delisted from Nasdaq First North Growth Market.... ► Artikel lesen | |
| 14:00 | Scandion Oncology A/S: Scandion Oncology has applied for delisting of the company's shares from Nasdaq First North Growth Market | The liquidator of Scandion Oncology (the "Company") has today submitted an application for delisting of the Company's shares from Nasdaq First North Growth Market. The last day of trading in the Company's... ► Artikel lesen | |
| 27.03. | Scandion Oncology A/S: Scandion Oncology Announces Results of Annual General Meeting | The Annual General Meeting 2025 of Scandion Oncology A/S in liquidation (the "Company") was held on 27 March 2025 at 2:00 p.m.
All proposals were adopted in accordance with the notice.As such, the Company... ► Artikel lesen | |
| 13.03. | The observation status for Scandion Oncology A/S is updated | On February 27, 2025, the shares and equity rights in Scandion Oncology A/S (the "Company") were given observation status with reference to information that the Company's board of directors would... ► Artikel lesen | |
| 13.01. | Scandion Oncology A/S: Scandion Oncology announces final data from the CORIST trial and is ready to move into a randomized phase II Proof of Concept trial in Colorectal Cancer | Scandion Oncology, an innovative drug efflux pump inhibition company using biomodulation capability to revert drug resistance, announces final data from CORIST trial part 1, 2 and 3. In this phase I/II... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen.
Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen,
bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen
Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu
verstehen sein kann.